Janux Therapeutics, Inc.JANXNASDAQ
LOADING
|||
Switch Symbol:
R&D Expense Growth Under Pressure
Trending lower, below historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
-0.10%
↓ 100% below average
Average (22q)
23.98%
Historical baseline
Range
High:146.08%
Low:-20.32%
Volatility
693.9%
High variability
| Period | Value |
|---|---|
| Q3 2025 | -0.10% |
| Q2 2025 | 38.35% |
| Q1 2025 | 20.42% |
| Q4 2024 | 11.78% |
| Q3 2024 | 24.94% |
| Q2 2024 | 5.88% |
| Q1 2024 | 14.94% |
| Q4 2023 | 2.93% |
| Q3 2023 | -20.32% |
| Q2 2023 | -5.93% |
| Q1 2023 | 2.79% |
| Q4 2022 | 12.35% |
| Q3 2022 | -2.48% |
| Q2 2022 | 38.32% |
| Q1 2022 | -8.82% |
| Q4 2021 | 32.87% |
| Q3 2021 | 77.45% |
| Q2 2021 | 146.08% |
| Q1 2021 | 95.43% |
| Q4 2020 | 18.11% |
| Q3 2020 | 23.92% |
| Q2 2020 | 22.59% |
| Q1 2020 | 0.00% |